Advances in the study of pyrotinib for the treatment of HER2-positive breast cancer.

Breast Cancer Res · 2026 · PMC13169558 · PMID 41776549

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

6.8 months; HR = 0.39; P < 0.0001) and exhibited a favorable trend toward improved OS [ 41 ] .

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.